PMID- 36312002
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 13
IP  - 10
DP  - 2022 Oct 15
TI  - Effectiveness and safety of human umbilical cord-mesenchymal stem cells for 
      treating type 2 diabetes mellitus.
PG  - 877-887
LID - 10.4239/wjd.v13.i10.877 [doi]
AB  - BACKGROUND: Progressive pancreatic beta-cell dysfunction is a fundamental part of 
      the pathology of type 2 diabetes mellitus (T2DM). Cellular therapies offer novel 
      opportunities for the treatment of T2DM to improve the function of islet beta-cells. 
      AIM: To evaluate the effectiveness and safety of human umbilical cord-mesenchymal 
      stem cell (hUC-MSC) infusion in T2DM treatment. METHODS: Sixteen patients were 
      enrolled and received 1 x 10(6) cells/kg per week for 3 wk as intravenous hUC-MSC 
      infusion. The effectiveness was evaluated by assessing fasting blood glucose, 
      C-peptide, normal glycosylated hemoglobin A1c (HbA1c), insulin resistance index 
      (homeostatic model assessment for insulin resistance), and islet beta-cell function 
      (homeostasis model assessment of beta-cell function). The dosage of hypoglycemic 
      agents and safety were evaluated by monitoring the occurrence of any adverse 
      events (AEs). RESULTS: During the entire intervention period, the fasting plasma 
      glucose level was significantly reduced [baseline: 9.3400 (8.3575, 11.7725), day 
      14 +/- 3: 6.5200 (5.2200, 8.6900); P < 0.01]. The HbA1c level was significantly 
      reduced on day 84 +/- 3 [baseline: 7.8000 (7.5250, 8.6750), day 84 +/- 3: 7.150 
      (6.600, 7.925); P < 0.01]. The patients' islet beta-cell function was significantly 
      improved on day 28 +/- 3 of intervention [baseline: 29.90 (16.43, 37.40), day 28 +/- 
      3: 40.97 (19.27, 56.36); P < 0.01]. The dosage of hypoglycemic agents was reduced 
      in all patients, of whom 6 (50%) had a decrement of more than 50% and 1 (6.25%) 
      discontinued the hypoglycemic agents. Four patients had transient fever, which 
      occurred within 24 h after the second or third infusion. One patient (2.08%) had 
      asymptomatic nocturnal hypoglycemia after infusion on day 28 +/- 3. No liver damage 
      or other side effects were reported. CONCLUSION: The results of this study 
      suggest that hUC-MSC infusion can improve glycemia, restore islet beta-cell 
      function, and reduce the dosage of hypoglycemic agents without serious AEs. Thus, 
      hUC-MSC infusion may be a novel option for the treatment of T2DM.
CI  - (c)The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Lian, Xiao-Fen
AU  - Lian XF
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Lu, Dong-Hui
AU  - Lu DH
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Liu, Hong-Li
AU  - Liu HL
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Liu, Yan-Jing
AU  - Liu YJ
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Han, Xiu-Qun
AU  - Han XQ
AD  - Department of Research & Development, Zhejiang MaiDa Gene Tech Co. Ltd, Zhoushan 
      316000, Zhejiang Province, China.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Endocrinology, Huizhou Central People's Hospital, Huizhou 516000, 
      Guangdong Province, China.
FAU - Lin, Yuan
AU  - Lin Y
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Zeng, Qing-Xiang
AU  - Zeng QX
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Huang, Zheng-Jie
AU  - Huang ZJ
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Xie, Feng
AU  - Xie F
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Huang, Cai-Hao
AU  - Huang CH
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China.
FAU - Wu, Hong-Mei
AU  - Wu HM
AD  - Department of Endocrinology, Longgang District Central Hospital of Shenzhen, 
      Shenzhen 518000, Guangdong Province, China.
FAU - Long, Ai-Mei
AU  - Long AM
AD  - Department of Endocrinology, Longgang District Central Hospital of Shenzhen, 
      Shenzhen 518000, Guangdong Province, China.
FAU - Deng, Ling-Ping
AU  - Deng LP
AD  - Department of Endocrinology, Longgang District Central Hospital of Shenzhen, 
      Shenzhen 518000, Guangdong Province, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 
      518000, Guangdong Province, China. bjdxszyynfm@163.com.
LA  - eng
PT  - Clinical Trial
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC9606793
OTO - NOTNLM
OT  - Blood glucose
OT  - Homeostasis model assessment of beta-cell function
OT  - Human umbilical cord mesenchymal stem cells
OT  - Hypoglycemic agents
OT  - Type 2 diabetes
COIS- Conflict-of-interest statement: The authors have no conflicts of interest to 
      declare.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/10/15
CRDT- 2022/10/31 04:31
PHST- 2022/06/06 00:00 [received]
PHST- 2022/08/19 00:00 [revised]
PHST- 2022/09/08 00:00 [accepted]
PHST- 2022/10/31 04:31 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/10/15 00:00 [pmc-release]
AID - 10.4239/wjd.v13.i10.877 [doi]
PST - ppublish
SO  - World J Diabetes. 2022 Oct 15;13(10):877-887. doi: 10.4239/wjd.v13.i10.877.